UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000055939 |
|---|---|
| Receipt number | R000063864 |
| Scientific Title | Phase II study of gemcitabine, dexamethasone, cisplatin, and rituximab (GDP-R) plus epcoritamab therapy for older transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma |
| Date of disclosure of the study information | 2024/11/01 |
| Last modified on | 2026/05/09 09:08:24 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2024/10/25 07:03:59 | ||
| 2 | Update | 2024/11/01 13:30:06 | Recruitment status |
|
| 3 | Update | 2025/04/25 09:32:08 | Email1 |
|
| 4 | Update | 2025/09/17 09:16:49 | Other related information Other related information |
|
| 5 | Update | 2026/04/02 03:07:25 | Recruitment status Other related information |
|
| 6 | Update | 2026/04/27 10:24:07 | Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
| 7 | Update | 2026/05/07 07:40:28 | Recruitment status Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded Other related information Other related information |
|
| 8 | Update | 2026/05/09 09:08:24 | Number of participants that the trial has enrolled Results Results Results date posted |
